AC Immune SA (NASDAQ:ACIU) Short Interest Update

AC Immune SA (NASDAQ:ACIU) saw a large decrease in short interest in April. As of April 15th, there was short interest totalling 509,400 shares, a decrease of 9.1% from the March 31st total of 560,600 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average trading volume of 180,700 shares, the short-interest ratio is presently 2.8 days.

AC Immune Trading Up 2.6 %

NASDAQ:ACIU opened at $2.35 on Monday. The company has a market capitalization of $232.42 million, a P/E ratio of -3.31 and a beta of 1.00. AC Immune has a twelve month low of $1.78 and a twelve month high of $5.14. The firm has a 50-day moving average price of $3.09 and a two-hundred day moving average price of $3.34.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $16.71 million for the quarter, compared to analyst estimates of $16.36 million. On average, equities research analysts predict that AC Immune will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On AC Immune

Several institutional investors have recently modified their holdings of the company. BVF Inc. IL lifted its stake in AC Immune by 96.2% during the fourth quarter. BVF Inc. IL now owns 14,571,236 shares of the company’s stock valued at $72,856,000 after buying an additional 7,142,857 shares in the last quarter. Avidity Partners Management LP boosted its holdings in AC Immune by 50.5% in the 4th quarter. Avidity Partners Management LP now owns 4,469,080 shares of the company’s stock valued at $22,345,000 after purchasing an additional 1,499,280 shares during the period. Platinum Investment Management Ltd. lifted its holdings in AC Immune by 14.6% during the 4th quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company’s stock valued at $7,578,000 after purchasing an additional 193,123 shares during the last quarter. Nixon Peabody Trust Co. bought a new position in AC Immune during the 4th quarter valued at about $64,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in AC Immune in the 4th quarter valued at about $48,000. Institutional investors own 51.36% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of AC Immune in a report on Friday, March 15th.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.